The information contained in these releases was current on the date the releases were issued and will become outdated over time. Lilly does not assume any responsibility for updating information in these releases.
Releases
 |
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Nov 18, 2009
|
11.2 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardi...
|
|
Lilly Surpasses United Way 2009 Campaign Goal
Nov 16, 2009
|
9.4 KB |
|
| |
INDIANAPOLIS, Nov 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) Chairman, President and Chief Executive Officer John Lechleiter today presented a $12 million check to the United Way. The check represents the contributions of Lilly's U.S. employees and retirees and a matching gift amount from the Lilly...
|
|
Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
12.6 KB |
|
| |
ORLANDO, Florida, Nov 15, 2009 (PR Newswire Europe via COMTEX News Network) -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
14.6 KB |
|
| |
ORLANDO, Fla., Nov 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
Nov 13, 2009
|
9.9 KB |
|
| |
INDIANAPOLIS, Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, will retire from Lilly effective February 28, 2010. Lilly has also announced that Jan M. Lundberg, Ph....
|
|
Deadline Extended to December 16 to Submit Nominations for Depression Awards Program
Nov 11, 2009
|
10.9 KB |
|
| |
NEW YORK, Nov 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The deadline to submit nominations for this year's Welcome Back Awards, a national awards program that honors outstanding individuals in the depression community, has been extended by one month. Nominations are now due by Wednesday, December 16, 2009.
The Welcome Back Awards...
|
|
Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day
Nov 9, 2009
|
15.0 KB |
|
| |
NEW YORK, Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The award-winning documentary Life for a Child will make its world television debut on the Sundance Channel on World Diabetes Day - Nov. 14, 2009, at 8 p.m. EST/PST.
Directed by Academy Award(R) nominee Edward Lachman, the film follows the journeys of children with type 1 dia...
|
|
Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer
Nov 4, 2009
|
11.8 KB |
|
| |
INDIANAPOLIS, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- "Feel. Create. Share the hope." With these words, Lilly USA, LLC, and the National Coalition for Cancer Survivorship (NCCS) kick off the 2010 Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition. The biennial competition invites residents of...
|
|
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Nov 2, 2009
|
15.0 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Nov 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA(R) (exenatide) injection.
"The FDA update issued today aligns ...
|
|
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Oct 30, 2009
|
15.8 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA(R) (exenatide) injection. BYETTA is now approved for use as a st...
|
|
Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'
Oct 30, 2009
|
10.4 KB |
|
| |
SAN DIEGO, Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- In a speech today to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "re...
|
|
Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
Oct 29, 2009
|
13.8 KB |
|
| |
SAN DIEGO, Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast. The facility, known as the "Lilly Biotechnology Center - San Diego," is opening three mon...
|
|
November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers
Oct 27, 2009
|
12.3 KB |
|
| |
INDIANAPOLIS, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year.(1) It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting fro...
|
|
Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
Oct 21, 2009
|
12.5 KB |
|
| |
MONTREAL, Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- IDF World Diabetes Congress Marks Major Milestone and Availability of Tools in 68 Countries, 31 Different LanguagesThis October marks the one-year anniversary of the international launchof the ground-breaking diabetes Conversation Map(TM) education tools. Created by Healthy In...
|
|
Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day
Oct 21, 2009
|
8.4 KB |
|
| |
INDIANAPOLIS, Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- More than 25 Eli Lilly and Company (NYSE: LLY) facilities around the world today will celebrate "Energy Day," which is a new corporate sustainability effort designed to educate Lilly employees about the company's latest energy reduction goals and to encourage sustainable b...
|
|
Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance
Oct 21, 2009
|
36.5 KB |
|
| |
INDIANAPOLIS, Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
-- Higher volume drives revenue growth
-- Stronger dollar results in improved gross margin
-- Earnings per share increase to $.86 (reported) or $1.20 (pro forma
non-GAAP)
-- Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (rep...
|
|
GE and Lilly Achieve Significant Advancement in Cancer Research
Oct 21, 2009
|
10.8 KB |
|
| |
New York, NY and Indianapolis, IN - October 21, 2009 - Scientists at GE Global Research (NYSE: GE), and researchers at Eli Lilly and Company (NYSE: LLY) today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
Working together, the research teams have deve...
|
|
Lilly Declares Fourth-Quarter Dividend
Oct 19, 2009
|
6.6 KB |
|
| |
INDIANAPOLIS, Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2009 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters of 2009 and brings the total annual dividen...
|
|
Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries
Oct 14, 2009
|
10.3 KB |
|
| |
INDIANAPOLIS, Oct 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced the sale of its Tippecanoe Laboratories manufacturing facility to Evonik Industries AG, one of the world's largest chemical companies. The manufacturing site, located in Lafayette, Indiana, will remain in operation with a f...
|
|
New Survey Reveals Even After 12 Years of Living With Depression Adults Still Struggle Due to Lack of Basic Information
Oct 14, 2009
|
14.3 KB |
|
| |
INDIANAPOLIS, Oct 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well.(i) Furthermore, on average, it took about six years for respondents...
|
|
|
